Cefminox

Cefminox
Clinical data
AHFS/Drugs.com	International Drug Names
Routes of; administration	IM, IV
ATC code	J01DC12 (WHO) ;
Legal status
Legal status	In general: ℞ (Prescription only);
Identifiers
	IUPAC name (6R,7S)-7-(((((2S)-2-amino-2-carboxyethyl)thio)acetyl)amino)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid;
CAS Number	84305-41-9 ;
PubChem CID	71141;
ChemSpider	64286 ;
UNII	PW08Y13465;
KEGG	D07642 ;
ChEMBL	ChEMBL1276342 ;
Chemical and physical data
Formula	C16H21N7O7S3
Molar mass	519.57 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C2N1/C(=C(\CS[C@@H]1[C@]2(OC)NC(=O)CSC[C@H](C(=O)O)N)CSc3nnnn3C)C(=O)O;
	InChI InChI=1S/C16H21N7O7S3/c1-22-15(19-20-21-22)33-4-7-3-32-14-16(30-2,13(29)23(14)10(7)12(27)28)18-9(24)6-31-5-8(17)11(25)26/h8,14H,3-6,17H2,1-2H3,(H,18,24)(H,25,26)(H,27,28)/t8-,14-,16+/m1/s1 ; Key:JSDXOWVAHXDYCU-VXSYNFHWSA-N ;
(what is this?) (verify)

Cefminox (INN) is a second-generation cephalosporin antibiotic.[1][2]

Spectrum

Cefminox is a broad-spectrum, bactericidal cephalosporin antibiotic. It is especially effective against Gram-negative and anaerobic bacteria. The following represents MIC data for a few medically significant microorganisms.

Clostridium difficile: 2 - 4 µg/ml
Escherichia coli: 0.125 - 16 µg/ml
Pseudomonas aeruginosa: 256 µg/ml[3]

References

Torres AJ, Valladares LD, Jover JM, Sánchez-Pernaute A, Frías J, Carcas AJ, et al. (September 2000). "Cefminox versus metronidazole plus gentamicin intra-abdominal infections: a prospective randomized controlled clinical trial". Infection. 28 (5): 318–22. doi:10.1007/s150100070027. PMID 11073141.
US 8497086, "Reaction Medium For Methicillin-Resistant Staphylococcus Aureus (MRSA) Bacteria", issued 20 July 2013, assigned to Biomereux
"Cefminox sodium Susceptibility and Minimum Inhibitory Concentration (MIC) Data" (PDF). www.toku-e.com.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Torres AJ, Valladares LD, Jover JM, Sánchez-Pernaute A, Frías J, Carcas AJ, et al. (September 2000). "Cefminox versus metronidazole plus gentamicin intra-abdominal infections: a prospective randomized controlled clinical trial". Infection. 28 (5): 318–22. doi:10.1007/s150100070027. PMID 11073141.

[2] US 8497086, "Reaction Medium For Methicillin-Resistant Staphylococcus Aureus (MRSA) Bacteria", issued 20 July 2013, assigned to Biomereux

[3] "Cefminox sodium Susceptibility and Minimum Inhibitory Concentration (MIC) Data" (PDF). www.toku-e.com.